Feedback
Settings

Settings

Goto Application

409,646 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 40,965
1.WO/2025/144772IMPROVED COMPOSITIONS AND METHODS FOR FECAL MICROBIOTA TRANSPLANTATION AND MICROBIOTA TRANSPLANT THERAPIES
WO - 03.07.2025
Int.Class A61K 35/741
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
 Appl.No PCT/US2024/061651 Applicant REGENTS OF THE UNIVERSITY OF MINNESOTA Inventor SADOWSKY, Michael, J.
The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.
2.WO/2025/139041OPHTHALMIC FORMULATION COMPRISING ANIMAL AQUEOUS HUMOR EXTRACT, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO - 03.07.2025
Int.Class A61K 35/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
 Appl.No PCT/CN2024/117677 Applicant THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY Inventor LIANG, Yuanbo
An ophthalmic formulation comprising an animal aqueous humor extract, a preparation method therefor, and use thereof. The aqueous humor is similar in composition to serum, and has lower metabolites, thereby enabling protection of the starvation-induced corneal epithelium. The ophthalmic formulation comprising the animal aqueous humor extract has the effect of treating xerophthalmia.
3.WO/2025/144801VACCINES FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES IN INVERTEBRATES
WO - 03.07.2025
Int.Class A61K 39/125
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
125Picornaviridae, e.g. calicivirus
 Appl.No PCT/US2024/061728 Applicant DALAN ANIMAL HEALTH, INC. Inventor WEINBERG, Isaac
The disclosure provides compositions and methods for treating and vaccinating invertebrates and invertebrate populations from diseases.
4.WO/2025/142752TAL EFFECTOR NUCLEASE PAIR AND USE THEREOF
WO - 03.07.2025
Int.Class C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
 Appl.No PCT/JP2024/045076 Applicant YAHATA Naoki Inventor YAHATA Naoki
The present invention provides a technology capable of more specifically cutting one of mutant mtDNA and wild-type mtDNA. This TAL effector nuclease pair includes a first TAL effector nuclease monomer and a second TAL effector nuclease monomer in which a target sequence is located 12-20 bases apart, and which each include a DNA-binding domain that includes RVDs and that binds to DNA having 8-15 bases, and a DNA cleavage domain of the FokI endonuclease. The RVDs include a first RVD that recognizes a base at the position of a mitochondrial disease-inducing mutation and a second RVD that recognizes a base at a position other than that of the mitochondrial disease-inducing mutation. The first RVD is at least one among NM that recognizes adenine, WK that recognizes guanine, and LK that recognizes guanine. The second RVD recognizes adenine by NI and recognizes guanine by NN.
5.WO/2025/142932COMPOSITION CONTAINING EXTRACELLULAR VESICLES DERIVED FROM MICROALGAE
WO - 03.07.2025
Int.Class A61K 36/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
02Algae
 Appl.No PCT/JP2024/045706 Applicant ROHTO PHARMACEUTICAL CO., LTD. Inventor OKADA,Keita
The purpose of the present invention is to provide a composition that contains extracellular vesicles derived from microalgae and has suppressed discoloration.　In one embodiment of the present invention, a composition containing (A) extracellular vesicles derived from microalgae, (B) a polyhydric alcohol, and (C) at least one chemical selected from the group consisting of organic acids, salts thereof, and nonionic surfactants, is prepared.
6.WO/2025/144762REPROGRAMMED CELL MODULATION OF CANCER MICROENVIRONMENT BY TUMOR HOMING PERSONALIZED REGENERATIVE CELLS
WO - 03.07.2025
Int.Class C12N 5/0775
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
077Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
0775Mesenchymal stem cells; Adipose-tissue derived stem cells
 Appl.No PCT/US2024/061565 Applicant IMMORTA BIO, INC. Inventor ICHIM, Thomas, E.
Disclosed are methods of augmenting efficacy of oncology therapies by providing reprogrammed cells such as personalized regenerative cells that modulate the tumor microenvironment. In one embodiment, somatic cells are dedifferentiated into OCT-4 expressing cells and endowed with tumor homing properties through culture or gene engineering. Once a stable population of tumor homing cells is established, such cells are made to express immune stimulating agents constitutively, or selectively upon entering the cancer microenvironment. Selective expression of immune stimulatory agents can be induced by exposure to hypoxia, acidosis, immune suppressive signaling or inflammatory signaling.
7.WO/2025/145122METHOD OF USING OF A FUNCTIONALLY CLOSED CELL PROCESSING SYSTEM
WO - 03.07.2025
Int.Class C12M 1/36
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
36including condition or time responsive control, e.g. automatically controlled fermentors
 Appl.No PCT/US2024/062193 Applicant TRENCHANT BIOSYSTEMS, INC. Inventor COELHO, Philip, H.
A method for enhancing genetic modification of target cells through automated spinoculation within a functionally closed cell processing platform. The process begins with introducing a cell suspension into a tapered cell processing cassette (CPC) that facilitates sedimentation and concentration of target cells. Genetic modification is achieved by injecting a gene transfer vector into the CPC, followed by controlled spinoculation to enhance vector-cell interaction through centrifugal force while maintaining optimal temperature and conditions. Optical sensors and automated feedback systems monitor and adjust centrifugation parameters to maximize transduction efficiency and cell viability. The method includes precise mixing, reagent delivery, washing to remove contaminants, and harvesting of genetically modified cells, all within a sterile environment. Additional features include buoyant microbubble separation, multi-mode centrifugation, and automated fluid handling via transfer syringe cassettes, ensuring efficient, contamination-free cell processing suitable for therapeutic applications.
8.WO/2025/145016CORNEAL ENDOTHELIAL CELL (CEC) CULTURING METHODS AND COMPOSITIONS
WO - 03.07.2025
Int.Class C12N 5/079
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
079Neural cells
 Appl.No PCT/US2024/062074 Applicant AURION BIOTECH, INC. Inventor LACOSTE, Arnaud
Provided herein are methods and compositions for culturing corneal endothelial cells (CECs) to increase the number of cells that may be expanded from a single corneal donor. The resulting compositions can be used in CEC therapies to treat corneal endothelial diseases.
9.WO/2025/144085METHOD FOR TREATING PAIN
WO - 03.07.2025
Int.Class A61K 36/25
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
 Appl.No PCT/RU2024/050306 Applicant KOSMODEMIANSKII, Leonid Vladimirovich Inventor KOSMODEMIANSKII, Leonid Vladimirovich
The invention relates to medicine, and more particularly to algology, and can be used in the treatment of pain. The present method includes oral administration of a pharmaceutical composition. Administration begins with a minimum single dose comprising: 1 drop or granule of the composition, dissolved in 15 ml of water, per 10 kg of the patient’s weight. The minimum single dose is administered every 15 minutes. An individually tailored single dose is determined by adding up the minimum doses of the composition which induce a subjective sensation of a decrease in pain. The composition is administered in the individually tailored single dose at a dosage frequency of not more than 8 times a day on the first day and not more than four times a day on the second and subsequent days. The pharmaceutical composition contains equal quantities of Eupatorium perfoliatum in a 3D dilution, China officinalis, Secale comutum, Arnica montana in a 3C dilution, Rhus toxicodendron in a 4C dilution, Aconitum napellus, Belladonna, Bryonia alba, Ipecacuanha, Nux vomica in a 5C dilution, Mercurius solubilis in a 6C dilution, Abrotanum, Gallicum acidum, Heloderma suspectum, Senecio aureus in a 7C dilution, and Stramonium in a 9C dilution. The invention provides for a significant decrease in the pain sensations experienced by the patient, irrespective of the source of and reasons for the pain.
10.WO/2025/140679A LIVE BACTERIA STRAIN OF STAPHYLOCOCCUS SP.
WO - 03.07.2025
Int.Class C12N 1/21
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
21modified by introduction of foreign genetic material
 Appl.No PCT/CN2024/143562 Applicant SHANGHAI YUGUAN BIOTECH CO., LTD. Inventor ZHANG, Mengya
Provided are a live bacteria strain of Staphylococcus sp., such as a live bacteria strain of Staphylococcus aureus, with reduced activity of saePQRS, reduced activity of adsA, and/or reduced production of capsules; the uses of said live bacteria strain; a vaccine against bacterial infection comprising said live bacteria strain; and a method for preventing and/or treating bacterial infection in a subject by administering said live bacteria strain.
# -